

BIODELIVERY SCIENCES INTERNATIONAL INC  
Form 8-K/A  
September 01, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K/A**  
**(Amendment No. 1)**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 1, 2017 (February 27, 2017)**

**BioDelivery Sciences International, Inc.**  
**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**001-31361**  
**(Commission**  
**File Number)**

**35-2089858**  
**(IRS Employer**  
**Identification No.)**

**4131 ParkLake Ave., Suite #225**

**Raleigh, NC**  
**(Address of principal executive offices)**

**27612**  
**(Zip Code)**

**Registrant's telephone number, including area code: 919-582-9050**

**Not Applicable**

**(Former name or former address if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

### EXPLANATORY NOTE

This Amendment No. 1 to Form 8-K (this Form 8-K/A ) amends the Current Report on Form 8-K (the Form 8-K ) originally filed by BioDelivery Sciences International, Inc. (the Company ) with the Securities and Exchange Commission on February 27, 2017.

The sole purpose of this Form 8-K/A is to file as a replacement exhibit to the 8-K an updated redacted version of the Term Loan Agreement (the Loan Agreement ) by and among the Company and the Company's wholly-owned subsidiaries, on the one hand, and CRG Servicing LLC, on the other hand. The remainder of the Form 8-K remains unchanged.

#### **Item 9.01 Financial Statements and Exhibits.**

##### *(d) Exhibits*

#### **Exhibit**

<b>No.</b>	<b>Description</b>
10.1	<u>Term Loan Agreement, dated February 21, 2017, among the Company, its wholly owned subsidiaries and CRG Servicing LLC, as administrative agent, and certain lenders named therein. (*)</u>

\* Confidential treatment is requested for certain portions of this exhibit pursuant to 17 C.F.R. Sections 200.8(b)(4) and 240.24b-2.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIODELIVERY SCIENCES INTERNATIONAL, INC.

Dated: September 1, 2017

By: /s/ Ernest R. De Paolantonio  
Name: Ernest R. De Paolantonio  
Title: Chief Financial Officer, Treasurer and  
Secretary